Microbiome, Dietary and Quality of Life Analysis of People Living With CVID Treated With or Without Immunoglobulins.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Enrollment
- 70
- Locations
- 2
- Primary Endpoint
- Primary outcomes
Study Overview
Brief Summary
Our research group focusses on finding evidence-based diet strategies to overcome immune dysregulation either due to immune checkpoint inhibitors (ICI) or common variable immunodeficiency (CVID) (Figure 1). CVID is an inborn error of immunity, which is defined, among other factors, by a low level of immunoglobulins, resulting in an increased risk of infections, auto-immune/inflammatory diseases, and cancer.
The gut microbiome (GM) plays a crucial role in maintaining immune homeostasis and modulating the host's innate and adaptive immune responses. Modulation of the GM can be achieved by dietary interventions that have been demonstrated to change the composition of the GM within 2 weeks (Oliver et al., 2021). The intake of more than 30 different plant products (vegetables, fruits, seeds and grains) on a weekly basis is associated with a more diverse microbiome in healthy adults (McDonald et al., 2018). Although direct proof of a link between diet and functioning of the immune system is lacking, it is striking that in a retrospective study, melanoma patients treated with immune checkpoint inhibitors (ICI) had a better overall survival when they consumed enough fibers without taking probiotics (Spencer et al., 2021). Currently, we have included 54 of 60 foreseen patients receiving ICI in an interventional study (FORX-01 (NCT05832606)) at our centre, providing them weekly with 30 different plants to be integrated in their diet (funded by Delhaize and FWO). The aim is to measure if the interventional group develops less immune-related adverse events (= side effects of ICI) by changing their GM.
Similarly, we hypothesize that introducing a fiber-rich diet in patients with CVID will result in a more diverse GM leading to a decrease in autoimmune disorders and infections and as such lead to an improvement of quality of life. To challenge this hypothesis, we plan to organize a similar diet trial, called KNIVES. To prepare this study, we will first perform an observational study to describe the microbiome of people with CVID (DELICIOUS) followed at UZ Brussel.
Study Design
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single group
- Primary Purpose
- Supportive care
- Masking
- None (open label)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- CVID diagnosis according to ESID criteria
- 18y or older
Exclusion Criteria
- start of therapeutic doses of antibiotics < 30 days prior to inclusion
- start of an immunomodulator < 30 days prior to inclusion Patient excluded for the above reasons will be able to step in the study at a later timepoint (30 days after start of antibiotics of immunomodulators)
Arms & Interventions
CVID participants of Observational cohort
Participants assigned to this arm will follow a high-fiber dietary intervention according to the study protocol. Clinical outcomes, gastrointestinal symptoms, dietary intake, and biological samples will be collected throughout the study to assess the effects of the intervention.
Intervention: Diet (Other)
Outcomes
Primary Outcomes
Primary outcomes
Time Frame: 1 year
To describe the gut microbiome of people living with CVID followed at UZ Brussel. To perform microbiome analysis through metagenomics (depending on availability, pricing, and emerging literature). To analyze one faecal sample of each participant at inclusion and additionally during infectious or autoinflammatory events. To assess microbiome diversity and composition, including: Alpha-diversity. Beta-diversity. Firmicutes/Bacteroidetes ratio (as a proximal marker for dysbiosis). Abundance of specific short-chain fatty acid-producing genera, including: Prevotella. Lactobacillaceae. Bifidobacteriaceae. Lachnospiraceae.
Secondary Outcomes
- Secondary outcome(1 year)
Investigators
Study Sites (2)
Identifiers
- NCT ID
- NCT07844668
- Other Study IDs
- DELICIOUS
Dates
- First Submitted
- (9 days ago)
- First Posted
- (2 days ago)
- Primary Completion
- (next year)
- Study Completion
- (next year)
- Last Verified
- (3 months ago)
- Last updated
- (2 days ago)
Regulatory & Sharing
- FDA Regulated Drug
- No
- FDA Regulated Device
- No
- IPD Sharing Plan
- No
- Has Results
- No
